BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 11502459)

  • 1. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
    Lubeck DP; Grossfeld GD; Carroll PR
    Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
    Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
    Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.
    Donovan KA; Gonzalez BD; Nelson AM; Fishman MN; Zachariah B; Jacobsen PB
    Psychooncology; 2018 Jan; 27(1):316-324. PubMed ID: 28557112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
    Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
    Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies.
    Alsinnawi M; Cullen J; Hurwitz LM; Levie KE; Burns JF; Rosner IL; Brand TC; Stroup S; Sterbis JR; Rice K; Conti G; Porter CR
    Can J Urol; 2019 Aug; 26(4):9809-9820. PubMed ID: 31469635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.
    Potosky AL; Reeve BB; Clegg LX; Hoffman RM; Stephenson RA; Albertsen PC; Gilliland FD; Stanford JL
    J Natl Cancer Inst; 2002 Mar; 94(6):430-7. PubMed ID: 11904315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
    Yamamoto S; Masuda H; Urakami S; Fujii Y; Sakamoto K; Kozuka T; Oguchi M; Fukui I; Yonese J
    Urology; 2015 Feb; 85(2):407-13. PubMed ID: 25623703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE.
    Arredondo SA; Elkin EP; Marr PL; Latini DM; DuChane J; Litwin MS; Carroll PR;
    Urology; 2006 Mar; 67(3):559-65. PubMed ID: 16527580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.